In Arad, MedLife-Genesys is growing very well, said Marcu, adding the company aims to conclude three to four transactions by yearend.
Talking about the issues on the local healthcare market, Marcu said that Romanian Health Insurance House has no leverage based on which it could pay the medics in state hospitals from the national public fund. “We currently talks about an organic growth by 20% of the medical services companies,” he said.
It is time that Romanian medical operators give a joint message and say what it could be done in Romania. Some local hospitals perform interventions in premiere for Europe.
According to Marcu, a local healthcare services provider will most certainly do a transaction abroad. Medlife planned to buy a Polish medical operator but it gave up as a result of the audit analysis. Local companies must expand in the neighboring countries, he said.
Many foreigners were amazed of the technology used in Romanian hospitals.
Marcu hopes the transaction with the minority stake in Medlife is concluded in one or two months.
Medlife aims to strengthen its position on the market and holds talks with various banks to make acquisitions. It therefore needs a partner willing to accept that, added Marcu.
ZF Pharma was organized by ZF in partnership with the Association of Pharmaceutical Distributors and Retailers in Romania, Antibiotice Iasi, Ionescu si Sava law firm, Bondoc si Asociatii law firm, EASI Logistic, Farmexpert, Honda Trading Romania, Janssen (part of Johnson & Johnson), McCann Erickson, Microsoft, PeliFilip, Porsche Finance Group and Terapia.
(English version by Manuela Panescu)